Prostate Cancer

Oncology / Haematology

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs. Second Novel Hormonal Therapy (NHT) in Patients with High Risk, Metastatic Castration-Resistant Prostate Cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Urothelial Cancer

Oncology / Haematology

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Urothelial Cancer

Oncology / Haematology

A Phase 3, Randomized, Double‐blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK‐3475) in Combination with Lenvatinib (E7080) Versus Pembrolizumab and Matching Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin‐ineligible Participants Whose Tumors Express PD‐L1 and in Any Platinum‐ineligible Participants

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Bladder Cancer

Oncology / Haematology

Adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non–muscle-invasive bladder cancer: a randomised phase 3 trial

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Bladder Cancer

Oncology / Haematology

A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Endothelial Cancer

Oncology / Haematology

Phase III double-blind randomised placebo controlled trial of Atezolizumab in combination with Paclitaxel and Carboplatin in women with advanced/recurrent endometrial cancer.

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Ovarian Cancer

Oncology / Haematology

A Phase II randomised trial comparing immune priming by low dose oral cyclophosphamide plus olaparib versus priming by olaparib alone, prior to combination therapy with olaparib plus durvalumab, versus single agent olaparib alone, in asymptomatic platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancers with homologous recombination repair defects

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Lung Cancer

Oncology / Haematology

A Phase 3, randomized, double-blinded, placebo-controlled study of Tiragolumab, an anti-Tigit-antibody, in combination with atezolizumab compared with placebo in combination with atezolizumab in patients with previously untreated locally advanced unresectable or metastatic PD-L1-selected Non-small cell lung cancer

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Breast Cancer

Oncology / Haematology

A Phase III Randomised, double blind, placebo controlled, multicentre study evaluating the efficacy and safety of GDC-9545 combined with Palbociclib in women with estrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer.

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4

Breast Cancer

Oncology / Haematology

A randomized phase II trial evaluating the efficacy of a nivolumab monotherapy lead in or commencement of nivolumab with paclitaxel and carboplatin as neo-adjuvant therapy in early stage triple negative breast cancers

Trial Phase

Non-drug Phase 1 Phase 2 Phase 3 Phase 4